Online Only Articles

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia

Guy’s and St Thomas’ NHS Foundation Trust, London
Guy’s and St Thomas’ NHS Foundation Trust, London
Guy’s and St Thomas’ NHS Foundation Trust, London
Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust and Faculty of Medicine, University of Southampton, UK
Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust and Faculty of Medicine, University of Southampton, UK
Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust and Faculty of Medicine, University of Southampton, UK
Guy’s and St Thomas’ NHS Foundation Trust, London
Vol. 102 No. 6 (2017): June, 2017 https://doi.org/10.3324/haematol.2017.163790